Literature DB >> 27918844

Novel method for facial rejuvenation using Er:YAG laser equipped with a spatially modulated ablation module: An open prospective uncontrolled cohort study.

N V Volkova1, L K Glazkova2, V V Khomchenko3, N S Sadick4.   

Abstract

Facial aging is a complex biological process that affects the skin and superficial musculoaponeurotic system (SMAS). A new technology (RecoSMA) for skin rejuvenation based on acoustic-interference method using Er:YAG laser (2936 nm) equipped with a special module SMA that targets both the dermis and SMAS was evaluated in an open-label prospective cohort study of 100 female patients treated for facial rejuvenation. Measure of clinical improvement included investigator-rated clinical photography using the Modified Fitzpatrick Wrinkle Scale, and ultrasound measurements in the dermis a week, 30 days and six months post treatment. All patients completed the study and no complications were noted. Improvements in skin tone and texture were noted in all participants and significant decrease in wrinkle depth was demonstrated at the six-month follow-up that was confirmed by ultrasound skin measurements. Data presented herein confirm the safety and efficacy of RecoSMA treatment for facial rejuvenation.

Entities:  

Keywords:  Er:YAG laser; RecoSMA; SMA module; facial rejuvenation

Mesh:

Year:  2016        PMID: 27918844     DOI: 10.1080/14764172.2016.1247964

Source DB:  PubMed          Journal:  J Cosmet Laser Ther        ISSN: 1476-4172            Impact factor:   2.247


  2 in total

1.  Treatment of Chronic Lower Extremity Ulcers with A New Er:Yag Laser Technology.

Authors:  J M Alcolea; E Hernández; P A Martínez-Carpio; M Vélez; V Khomchenko; A Sola; M A Trelles
Journal:  Laser Ther       Date:  2017-09-30

Review 2.  Effects of non-ablative Er:YAG laser on the skin and the vaginal wall: systematic review of the clinical and experimental literature.

Authors:  Lucie Hympanova; Katerina Mackova; Moetaz El-Domyati; Eva Vodegel; Jan-Paul Roovers; Jan Bosteels; Ladislav Krofta; Jan Deprest
Journal:  Int Urogynecol J       Date:  2020-08-11       Impact factor: 2.894

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.